SK Biopharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Dong Hoon Lee

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2.8yrs
CEO ownership	0.004%
Management average tenure	no data
Board average tenure	3.2yrs

Recent management updates

Recent updates

SK Biopharmaceuticals Co., Ltd. (KRX:326030) Shares Could Be 47% Below Their Intrinsic Value Estimate

Nov 27

There May Be Underlying Issues With The Quality Of SK Biopharmaceuticals' (KRX:326030) Earnings

Aug 22

SK Biopharmaceuticals Co., Ltd. (KRX:326030) Looks Just Right With A 25% Price Jump

Aug 21

Does This Valuation Of SK Biopharmaceuticals Co., Ltd. (KRX:326030) Imply Investors Are Overpaying?

May 22

SK Biopharmaceuticals Co., Ltd. (KRX:326030) Not Lagging Industry On Growth Or Pricing

Apr 09

Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?

Feb 27

We're Not Worried About SK Biopharmaceuticals' (KRX:326030) Cash Burn

Mar 12

CEO

Dong Hoon Lee (56 yo)

2.8yrs

Tenure

Mr. Dong Hoon Lee serves as Chief Executive Officer of SK Biopharmaceuticals Co., Ltd. since 2022 and also served as its Chairman of the Board since February 26, 2020. He is President of SK Biopharmaceutic...

Board Members

Name	Position	Tenure	Compensation	Ownership
Dong Hoon Lee	CEO, President & Executive Director	4.8yrs	no data	0.0038% ₩ 299.6m
Jiyoung Jung	CFO & Executive Director	less than a year	no data	no data
William Koster	Member of Advisory Board	no data	no data	no data
Gary Bennett	Member of Advisory Board	no data	no data	no data
Emilio Perucca	Member of Advisory Board	no data	no data	no data
Frank Castellana	Member of Advisory Board	no data	no data	no data
Linda Watkins	Member of Advisory Board	no data	no data	no data
H. White	Member of Advisory Board	no data	no data	no data
Min-Ji Kim	Independent Director	1.7yrs	no data	no data
Min Sop Song	Independent Chairman of the Board	5.3yrs	no data	no data
Yung Jue Bang	Chairman of the Scientific Advisory Board	1.3yrs	no data	no data
Hae Young Ahn	Independent Outside Director	5.3yrs	no data	no data

3.2yrs

Average Tenure

Experienced Board: A326030's board of directors are considered experienced (3.2 years average tenure).

SK Biopharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

SK Biopharmaceuticals Assembles Board of Prominent Experts to Boost Growth, Innovation

Insufficient new directors

SK Biopharmaceuticals Appoints Donghoon Lee as President of Company and U.S. Subsidiary Effective January 1, 2023

High number of new and inexperienced directors

Recent updates

SK Biopharmaceuticals Co., Ltd. (KRX:326030) Shares Could Be 47% Below Their Intrinsic Value Estimate

New major risk - Earnings quality

Consensus EPS estimates increase by 13%

There May Be Underlying Issues With The Quality Of SK Biopharmaceuticals' (KRX:326030) Earnings

SK Biopharmaceuticals Co., Ltd. (KRX:326030) Looks Just Right With A 25% Price Jump

Now 22% overvalued

Does This Valuation Of SK Biopharmaceuticals Co., Ltd. (KRX:326030) Imply Investors Are Overpaying?

SK Biopharmaceuticals Co., Ltd. to Report Q1, 2024 Results on May 09, 2024

SK Biopharmaceuticals Co., Ltd. (KRX:326030) Not Lagging Industry On Growth Or Pricing

Full year 2023 earnings released: ₩420 loss per share (vs ₩1,780 loss in FY 2022)

Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?

SK Biopharmaceuticals Co., Ltd. to Report Q4, 2023 Results on Jan 29, 2024

Consensus EPS estimates upgraded to ₩604 loss, revenue downgraded

SK Biopharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Nov 09, 2023

SK Biopharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Nov 09, 2023

Consensus EPS estimates fall by 11%

SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sk Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and Moped Molecular Glue Screening Platform At the 20Th Annual Discovery on Target Conference

Consensus EPS estimates fall by 14%

Price target increased by 9.2% to ₩105,308

SK Biopharmaceuticals Assembles Board of Prominent Experts to Boost Growth, Innovation

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 19%

Consensus estimates of losses per share improve by 17%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Now 21% undervalued

Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals' Seizure Detection Wearable Device At AES 2022

SK Biopharmaceuticals Appoints Donghoon Lee as President of Company and U.S. Subsidiary Effective January 1, 2023

SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969

Consensus estimates of losses per share improve by 12%

Consensus forecasts updated

Consensus forecasts updated

High number of new and inexperienced directors

Price target decreased to ₩110,167

Price target decreased to ₩108,200

Consensus revenue estimates fall by 16%

Price target decreased to ₩119,750

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Consensus EPS estimates have been upgraded.

No longer forecast to breakeven

Third quarter 2021 earnings released: ₩565 loss per share (vs ₩850 loss in 3Q 2020)

Forecast breakeven moved forward to 2022

Consensus EPS estimates increase to -₩2.68

Consensus forecasts updated

Consensus forecasts updated

Consensus EPS estimates increase to -₩608

We're Not Worried About SK Biopharmaceuticals' (KRX:326030) Cash Burn

CEO

Tenure

Board Members

Average Tenure